PRCT: $50.2M ADJUSTED EBITDA LOSS VS. $35M PROJECTED -- LEVI & KORSINSKY, LLP INVESTIGATES
Idag, 00:50
PRCT: $50.2M ADJUSTED EBITDA LOSS VS. $35M PROJECTED -- LEVI & KORSINSKY, LLP INVESTIGATES
PR Newswire
NEW YORK,, March 4, 2026
Procept BioRobotics reported one set of numbers to investors -- the actual figures told a different story
NEW YORK, , March 4, 2026 /PRNewswire/ -- Investors in Procept BioRobotics (NASDAQ: PRCT) lost more than 15% of their investment value after the Company disclosed financial results that diverged sharply from the figures management had presented. Those who suffered losses are encouraged to submit their information here . You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
On the Q3 2025 earnings call, CFO Kevin Waters projected a full-year 2025 adjusted EBITDA loss of approximately $35 million. When actual results were reported, the adjusted EBITDA loss was $50.2 million -- a gap of $15.2 million, or 43% worse than the figure investors were given. At the same time, management told investors handpiece average selling prices were being maintained at approximately $3,200, while the Company had eliminated historical bulk-purchase discounts that directly affected realized pricing.
Procept reported FY 2025 revenue of $308.1 million against guidance of $325.5 million. The Company's Q4 2025 EPS came in at -$0.53 versus the -$0.32 analyst consensus -- a 66% miss.
Shareholders who lost money on PRCT are encouraged to click here to discuss their legal rights . You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
Levi & Korsinsky, LLP -- Top 50 securities litigation firm (ISS, seven consecutive years). Over 70 professionals. Hundreds of millions recovered.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
SOURCE Levi & Korsinsky, LLP
Ämnen i artikeln
PRCT: $50.2M ADJUSTED EBITDA LOSS VS. $35M PROJECTED -- LEVI & KORSINSKY, LLP INVESTIGATES
Idag, 00:50
PRCT: $50.2M ADJUSTED EBITDA LOSS VS. $35M PROJECTED -- LEVI & KORSINSKY, LLP INVESTIGATES
PR Newswire
NEW YORK,, March 4, 2026
Procept BioRobotics reported one set of numbers to investors -- the actual figures told a different story
NEW YORK, , March 4, 2026 /PRNewswire/ -- Investors in Procept BioRobotics (NASDAQ: PRCT) lost more than 15% of their investment value after the Company disclosed financial results that diverged sharply from the figures management had presented. Those who suffered losses are encouraged to submit their information here . You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
On the Q3 2025 earnings call, CFO Kevin Waters projected a full-year 2025 adjusted EBITDA loss of approximately $35 million. When actual results were reported, the adjusted EBITDA loss was $50.2 million -- a gap of $15.2 million, or 43% worse than the figure investors were given. At the same time, management told investors handpiece average selling prices were being maintained at approximately $3,200, while the Company had eliminated historical bulk-purchase discounts that directly affected realized pricing.
Procept reported FY 2025 revenue of $308.1 million against guidance of $325.5 million. The Company's Q4 2025 EPS came in at -$0.53 versus the -$0.32 analyst consensus -- a 66% miss.
Shareholders who lost money on PRCT are encouraged to click here to discuss their legal rights . You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
Levi & Korsinsky, LLP -- Top 50 securities litigation firm (ISS, seven consecutive years). Over 70 professionals. Hundreds of millions recovered.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
SOURCE Levi & Korsinsky, LLP
Ämnen i artikeln
Analys
Börser
Iran
Analys
Mest läst
Börser
Iran
Marknadsöversikt
1 DAG %
Senast
1 mån
